Clinical prediction model for pediatric lymphadenopathy: enhancing diagnostic precision and treatment decision making
link.springer.com shows its articles on its own site.
Read the article on link.springer.com ↗Article · Jul 2024 · 1 min read
In brief
In brief
This study developed a clinical prediction model using 12 characteristics to distinguish benign from malignant lymphadenopathy in children under 15, achieving 98.6% accuracy for malignancy detection. The model helps clinicians reduce unnecessary biopsies while avoiding missed cancer diagnoses, though it tends toward conservative overestimation of malignancy risk.
- Clinical prediction model achieved 98.6% accuracy (AUROC 0.98) for identifying malignant pediatric lymphadenopathy using 12 clinical characteristics.
- Model incorporates lymph node size, location, duration, associated symptoms, and examination findings to stratify biopsy risk in children under 15.
- Tool intentionally overestimates malignancy risk to avoid missed diagnoses while reducing unnecessary biopsies in benign cases.
- Among 188 pediatric cases, 37.2% had benign pathology beyond reactive hyperplasia and 14.4% had malignancy, validating clinical decision support need.
- Overall accuracy of 68.3% for distinguishing reactive hyperplasia vs benign vs malignant suggests utility as triage tool rather than definitive diagnostic.
Written by the GCMD Library team from the article.
Abstract
Introduction
Lymph node enlargement is common in children, with 90% of physiologically palpable lymph nodes. This study aimed to develop a predictive model based on clinical characteristics to enhance the diagnosis of pediatric lymphadenopathy and provide insights into biopsy outcomes.
Materials and methods
A clinical prediction rule was developed using a retrospective, cross-sectional design for patients under 15 years who underwent lymph node biopsy from 2012 to 2022. Multivariable risk regression was used to analyze benign and malignant lesions, presenting results through risk difference and AUROC for each group. Predicted probabilities were applied in a logistic regression equation to classify patients’ lymphadenopathy as reactive hyperplasia, benign, or malignant.
Results
Of 188 children, 70 (37.2%) had benign lymphadenopathy beyond reactive hyperplasia, and 27 (14.4%) had malignant lymphadenopathy. The predictive model included 12 characteristics such as size, location, duration, associated symptoms, and lymph node examination. Predictive accuracy was 92.2% for benign cases (AUROC = 0.92; 95% CI 0.87–0.96) and 98.6% for malignancy (AUROC = 0.98; 95% CI 0.94–0.99). Overall accuracy for predicting both benign and malignant tumors was 68.3%.
Conclusion
The model demonstrated reasonably accurate predictions for the clinical characteristics of pediatric lymphadenopathy. It tended to overestimate malignancy but did not miss diagnoses, aiding in reducing unnecessary lymph node biopsies in benign cases.